Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Tal Zaks lands at Moderna as CMO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Merck KGaA to tap Oschmann as new CEO, sources report

Merck KGaA is the latest company to join Big Pharma's recent round of executive musical chairs. The German drugmaker is promoting deputy chief executive Stefan Oschmann to replace current CEO Karl-Ludwig Kley as the company's top dog.

Departed Salix execs score $47M with Valeant buyout

Valeant wasn't the only one that scored a win when Salix Pharmaceuticals agreed to its $173-per-share buyout offer. Two former Salix execs--who left the company recently amid inventory issues--will make a pretty penny on the deal as well.

Novartis faces more gender-bias claims with $110M Alcon suit

Several years ago, Novartis agreed to pay $175 million to settle a high-profile gender discrimination lawsuit focused on its U.S. sales operations. Now, the Swiss drugmaker faces a new discrimination fight at its Texas-based Alcon unit.

Old Allergan CEO Pyott won't join New Allergan's board

Allergan Chairman and CEO David Pyott fought long and hard to keep Valeant Pharmaceuticals from taking over his company. He engineered a $66 billion sale to ambitious Actavis instead, and the Allergan name now lives on as the merged company's moniker. But Pyott won't be sticking around to enjoy the results.

Pfizer chief gets a pay boost, but two underlings get bigger ones

Pfizer CEO Ian Read got a nice pay bump for 2015, with a total package of $23.3 million--more than one-quarter bigger than the previous year's total. But a big chunk of that increase came in the value of his pension. Back that out, and Read's compensation only grew by $280,000.

R&D exec Tal Zaks leaps from flagging Sanofi to fast-growing Moderna

While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal Zaks underscored the bright side of restructuring, being named chief medical officer at Moderna Therapeutics a month after he was among 100 oncology R&D staffers who were ushered out at Sanofi in a recent reorganization.

With drug discovery ambitions, 23andMe recruits Genentech vet Scheller

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

J&J boosts CEO pay to $25M, doubles R&D chief's haul

Johnson & Johnson CEO Alex Gorsky got a multimillion-dollar pat on the back for 2014. J&J's board upped his pay package to almost $25 million, with more cash, more options, and a much bigger chunk of J&J stock.

AstraZeneca adds hefty share grant to CEO's £3.5M pay

AstraZeneca CEO Pascal Soriot got a bit of a pay raise last year, with a 3% bump to his base salary. His bonus jumped, too, putting his salary, bonus and cash benefits at £3.5 million. But Soriot's real boost came in the form of equity that won't pay off for a few years: Some £4.8 million in shares, under the company's long-term incentive plan.